William Richard White Akero Therapeutics, Inc. (AKRO) insider trading activity

William Richard White is Chief Financial Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 46,799 shares of AKRO, which is worth approximately $1.03 Million. The most recent transaction as insider was on Jun 11, 2024, when has been sold 2,831 shares (Common Stock) at a price of $22.64 per share, resulting in proceeds of $64,093. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.8K

5.7% 3M change

145.02% 12M change

Total Value Held $1.03 Million

William Richard White Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 11 2024	SELL Open market or private sale	$64,093 $22.64 p/Share	2,831 Reduced 5.7%	46,799 Common Stock
Mar 13 2024	SELL Open market or private sale	$20,510 $28.33 p/Share	724 Reduced 1.44%	49,630 Common Stock
Dec 14 2023	SELL Open market or private sale	$12,684 $20.76 p/Share	611 Reduced 1.2%	50,354 Common Stock
Dec 08 2023	BUY Grant, award, or other acquisition	-	32,497 Added 38.94%	50,965 Common Stock
Sep 13 2023	SELL Open market or private sale	$31,814 $50.34 p/Share	632 Reduced 3.31%	18,468 Common Stock
Jun 20 2023	SELL Open market or private sale	$1,142,735 $55.0 p/Share	20,777 Reduced 52.1%	19,100 Common Stock
Jun 20 2023	BUY Exercise of conversion of derivative security	$122,675 $7.01 p/Share	17,500 Added 30.5%	39,877 Common Stock

Jun 13 2023	SELL Open market or private sale	$33,426 $55.16 p/Share	606 Reduced 2.64%	22,377 Common Stock
Mar 10 2023	SELL Payment of exercise price or tax liability	$27,864 $43.47 p/Share	641 Reduced 2.71%	22,983 Common Stock
Dec 28 2022	SELL Open market or private sale	$49,710 $49.76 p/Share	999 Reduced 4.06%	23,624 Common Stock
Dec 28 2022	BUY Exercise of conversion of derivative security	$7,002 $7.01 p/Share	999 Added 3.9%	24,623 Common Stock
Dec 27 2022	SELL Open market or private sale	$945,679 $49.77 p/Share	19,001 Reduced 44.58%	23,624 Common Stock
Dec 27 2022	BUY Exercise of conversion of derivative security	$133,197 $7.01 p/Share	19,001 Added 30.83%	42,625 Common Stock
Dec 09 2022	BUY Grant, award, or other acquisition	-	19,195 Added 44.83%	23,624 Common Stock
Oct 13 2022	SELL Open market or private sale	$796,400 $39.82 p/Share	20,000 Reduced 81.87%	4,429 Common Stock
Oct 13 2022	BUY Exercise of conversion of derivative security	$140,200 $7.01 p/Share	20,000 Added 45.02%	24,429 Common Stock
Sep 13 2022	SELL Open market or private sale	$882,375 $27.15 p/Share	32,500 Reduced 88.01%	4,429 Common Stock
Sep 13 2022	BUY Exercise of conversion of derivative security	$227,825 $7.01 p/Share	32,500 Added 46.81%	36,929 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$9,251 $8.03 p/Share	1,152 Added 20.64%	4,429 Common Stock
Jan 14 2022	SELL Open market or private sale	$213,691 $22.03 p/Share	9,700 Reduced 74.75%	3,277 Common Stock
Jan 14 2022	BUY Exercise of conversion of derivative security	$67,997 $7.01 p/Share	9,700 Added 42.77%	12,977 Common Stock
Dec 21 2021	SELL Open market or private sale	$2,200 $22.0 p/Share	100 Reduced 2.96%	3,277 Common Stock
Dec 21 2021	BUY Exercise of conversion of derivative security	$701 $7.01 p/Share	100 Added 2.88%	3,377 Common Stock
Dec 17 2021	SELL Open market or private sale	$70,528 $22.04 p/Share	3,200 Reduced 49.41%	3,277 Common Stock
Dec 17 2021	BUY Exercise of conversion of derivative security	$22,432 $7.01 p/Share	3,200 Added 33.07%	6,477 Common Stock

Also insider at

VTYX

Ventyx Biosciences, Inc. Healthcare

GMTX

Gemini Therapeutics, Inc. Healthcare

WRW